All News

PSA2L.jpg

Combination treatments in Psoriatic Arthritis

d Antoni Chan, MD, PhD

Despite the advances in the treatment of PsA with biologic (bDMARD) and targeted synthetic (tsDMARD), less than half of patients with this condition achieved remission or low disease activity. Combination DMARD treatment is often used in order to achieve remission or minimal disease activity. The standard practice is to use a conventional synthetic (csDMARD) with a bDMARD. The use of the combination of bDMARD with a tsDMARD such as a JAKi or TYK2i is a new order in the treatment of PsA.

Read Article
world globe with a line of people

Health inequities in rheumatology: A central theme

d Mrinalini Dey, MD

This year at EULAR, health inequalities have taken centre stage as fundamental drivers of outcomes in rheumatic and musculoskeletal diseases. Across multiple sessions and studies, delegates are presenting compelling evidence and ground-breaking research demonstrating that who you are, where you live, and what resources you can access truly do shape the trajectory of chronic illness just as much as biological factors.

Read Article
diversity together global leadership

Difficult-to-Manage AxSpA: Global Prevalence and Associated Factors

d Nelly Ziade

The concept of Difficult-to-Manage (D2M) axial spondyloarthritis (axSpA) is a recent development, with the first expert consensus definition published by the Assessment of SpondyloArthritis International Society (ASAS) earlier this year. This unified definition has stimulated a wave of new research globally, with multiple studies analysing D2M axSpA in diverse clinical cohorts.

Read Article
POCUS of the lung can detect subclinical ILD and can be a useful, inexpensive, easy to perform screening tool for CTD-ILD. #EULAR2025 @RheumNow https://t.co/KpH05w1S9O

Links:

Adela Castro AdelaCastro222 ( View Tweet)
LIVE Daily Recap – EULAR 2025 Coverage Date: Thursday, 06/12, Friday, 06/13 and Saturday, 06/14 Time: 12 (noon) ET 🔗 Tune in and join the conversation: YouTube, X, Facebook Live & LinkedIn #RheumNow#EULAR25 #Rheumatology #MedTwitter #HCPs #RheumatologyEducation https://t.co/1qlcKDOL64
Dr. John Cush RheumNow ( View Tweet)
📊 In a 40-yr cohort (n=2818), RA pts had 2.3x ↑ risk of DVT (HR 2.26) & 1.6x ↑ risk of PE (HR 1.61) vs non-RA. Risk ↑ with RF/CCP+, nodules (HR 2.9), BMI ≥30 (HR 1.9), & biologic use in year 1 (HR 2.4–2.9). Remission = ↓ PE risk (HR 0.47) 📍OP0070 @RheumNow #EULAR2025

Jiha Lee JihaRheum ( View Tweet)

POS0627: RA patients aged ≥90 yrs can benefit from biologics/JAKi! In 3,600 pts, 84% of those ≥90 achieved low disease activity, 71% were on JAKi. But serious infections occurred in 21%—mostly pneumonia. Use w/caution in the oldest-old. #EULAR2025 @rheumnow

Jiha Lee JihaRheum ( View Tweet)

#Probiotics +#methotrexate giving far more #remission in #rheumatoid #arthritis than #MTX alone? Seems fishy…. oops - #fish #oil #omega3 #fatty #acids do work! not sure re the huge benefit of ‘immunebiotics’ #EULAR2025 @RheumNow @eular_org abst#POS0483 https://t.co/STQuaOkBcY

Links:

Janet Pope Janetbirdope ( View Tweet)

Closing the care divide in #JIA treatment plenary session Overall theme in #EULAR2025 is everyone talking about AI and digital health on day 1 Biologics have changed the game! @RheumNow https://t.co/qDqbz8JApe

Links:

Bella Mehta bella_mehta ( View Tweet)
Data from a German cohort evaluated the frequency of D2M-axSpA using the new D2M definition and showed: > Female pts > Peripheral SpA symptoms < HLAB27 positive < Education level < Objective signs: MRI-inflammation in the spine or elevated CRP levels. also PROs were worse in

Adela Castro AdelaCastro222 ( View Tweet)

#EULAR2025 Abstr#OP0077 Which MSK item/tool is important when assessing #SLE arthritis?Cohort study showed: -SJC = good specificity. Correlated with US synovitis but not patient-defined response -New tool, LAMDA correlated with US & patient response. May be used in RCT @RheumNow https://t.co/srVLKw2pcL

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
❓️How effective and safe is it to combine bDMARDs and tsDMARDS (i.e. TNFi/ IL17i + JAKi/TYKi) in #psoriatic_arthritis? 🅰️ Reassuring data from a case-series study presented by Andre Lucas Ribeiro #EULAR2025 OP0090 @RheumNow #Strategy https://t.co/W8fuzSgxbJ

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
Ph 2 RCT Sonelokimab (IL-17A- & IL-17F-inhibiting Nanobody) 24wks 207 pts SON 120 MDA 51% vs. 45% ADA Subgroups: female 52%, weight ≥100kg 53%, ≥3% BSA 55% Composite ACR70/PASI100 SON 120 48% vs. 19% ADA No new safety signal Ph 3 on the way 2 doses SON 60 &120 #OP0096 https://t.co/w5QtpKbi1W

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Young Patients’ AREA empowers teens/young adults w/ autoimmune disease to shape research. US-based, youth-led & grounded in empowerment, they co-design studies, train peers & advise researchers. A truly positive and meaningful initiative esp for PPIE @RheumNow #EULAR2025 #OP0008

Mrinalini Dey DrMiniDey ( View Tweet)

Efficacy and safety of deucravacitinib up to week 52 in the POETYK PsA-2 study •ACR20 at W16: 54.2% (deucravacitinib) vs 39.4% (placebo), p=0.0002 •PASI75: 40.9% vs 15.4%, p<0.0001 •MDA: 25.6% vs 14.7%, p=0.0007 •FACIT-F: +2.5 vs +1.8 •SAE: 1.9% (low) TYK2 inhibition shows https://t.co/JXTZRk2itA

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
❓️Is early intensive therapy with combination csDMARDs or TNFi superior to standard step care for the treatment of moderate to severe #psoriatic_arthritis? 🅰️ Yes 🔅Check out the SPEED RCT presented by @DrLauraCoates at #EULAR2025 OP0089 @RheumNow #Strategy https://t.co/24e7wUV2FB

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2025 Abstr#OP0078 #Lupus nephritis is assoc with CVD. Propensity matched analysis comparing GLP-1 agonist vs SLGT2-i using TrinetX database in LN ->favourable risk reduction with GLP-1: -CKD progression -Mortality -MI Validation & mechanistic explanation needed @RheumNow https://t.co/xPDVDm1CHm

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In propensity-matched RA cohort (n=2,449 each) on JAK inhibitors, adding a GLP-1 agonist reduced risk of: • Acute coronary syndromes (RR 0.65, p=0.0009) • DVT (RR 0.69, p=0.007) Overall CV events ↓ by 33% (RR 0.67, p=0.0007) #EULAR2025 @RheumNow Abstract#OP0069 https://t.co/jWI6tvri8O

Links:

Jiha Lee JihaRheum ( View Tweet)
Can RA be intercepted? In the ALTO follow-up of the APIPPRA RCT (Cope et al), 1 year of abatacept delayed RA onset by up to 3 years in ACPA+/RF+ individuals. Effect strongest in those with mature autoantibody profiles. Abstract#OP0004 @RheumNow #EULAR2025 https://t.co/N7YwtYod8w

Links:

Jiha Lee JihaRheum ( View Tweet)
Repurposing drugs to #osteoarthritis No jewel in the rough! Most drugs - MTX, colchicine, TNFi, IL1i, etc are NEGATIVE or yield mixed results from diff #RCTs Not sure this is the way forward for #OA drug discovery 💡 #EULAR2025 @RheumNow @eular_org Abst#POS565 https://t.co/A6SdXtOo7v

Links:

Janet Pope Janetbirdope ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×